Physician profile
Nohemi Herrera
NPI 1437788122
$4,065.19
in general payments reported to CMS, 2019-2025
25 companies · $1,939 in 2025
The $1,939 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $298 · 2024: $1,828 · 2025: $1,939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,065.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,065.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $796.54 | 2023-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $554.59 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $419.78 | 2023-2025 | Otezla, Repatha, Otezla |
| Novo Nordisk INC | $293.95 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $287.37 | 2024-2025 | Jardiance, Synjardy, Ofev |
| Phathom Pharmaceuticals, INC. | $261.15 | 2024-2025 | Voquezna |
| Viiv Healthcare Company | $257.23 | 2024-2025 | Apretude |
| Janssen Pharmaceuticals, INC | $204.78 | 2024-2025 | Spravato |
| Merck Sharp & Dohme LLC | $168.08 | 2024-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Abbvie INC. | $157.44 | 2023-2025 | |
| Pfizer INC. | $142.99 | 2023-2025 | |
| Exact Sciences Corporation | $117.78 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $87.67 | 2023-2025 | Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $61.38 | 2023-2025 | Rexulti |
| Inspire Medical Systems, INC. | $44.45 | 2024 | Inspire |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $28.47 | 2024 | Gemtesa |
| Axsome Therapeutics, INC. | $25.51 | 2025 | Symbravo |
| Sanofi Pasteur INC. | $25.44 | 2025 | |
| Corium, LLC | $23.64 | 2023 | Azstarys |
| Abbott Laboratories | $22.41 | 2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $21.75 | 2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $16.67 | 2025 | Eliquis |
| Lundbeck LLC | $15.95 | 2025 | Rexulti |
| Currax Pharmaceuticals LLC | $15.44 | 2024 | Contrave, Onzetra Xsail |
| Kowa Pharmaceuticals America, INC. | $14.73 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nohemi Herrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.